Private company

Nabriva Therapeutics plc

Pharmaceutical preparations company1

In its 2023 annual report the company says: “We are a biopharmaceutical company that historically engaged in the commercialization and research and development of novel anti-infective agents to treat serious infections. We have the commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.”59

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersL21
  • Incorporated inIreland2
  • Business address25-28 North Wall Quay, Dublin, L2 D01 H1042
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-150.2%Operating margin3
-154.8%Net margin3
27.8%Revenue growth, 20223
-1736.6%Return on equity3
0.12×Debt to equity3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue32¢$28.6M
  • Research and development16¢$14.3M
  • Selling, general and admin50¢$45.3M
  • Interest1¢$698.0K
  • Income tax2¢$1.6M

Out of $36.9M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$36.9M in 2022+470% since 2016
0$10.0M$20.0M$30.0M$40.0M2016: $6.5M$6.5M20162017: $5.3M$5.3M2017−18%2018: $9.7M$9.7M2018+82%2019: $9.5M$9.5M2019−2%2020: $5.0M$5.0M2020−47%2021: $28.9M$28.9M2021+475%2022: $36.9M$36.9M2022+28%
Operating income45673-$55.5M in 2022+1% since 2016
-$150.0M-$100.0M-$50.0M02016: -$55.0M-$55.0M20162017: -$73.8M-$73.8M2017+34%2018: -$114.4M-$114.4M2018+55%2019: -$79.5M-$79.5M2019−31%2020: -$66.1M-$66.1M2020−17%2021: -$48.5M-$48.5M2021−27%2022: -$55.5M-$55.5M2022+14%
Net income45673-$57.2M in 2022+4% since 2016
-$150.0M-$100.0M-$50.0M02016: -$54.9M-$54.9M20162017: -$74.4M-$74.4M2017+35%2018: -$114.8M-$114.8M2018+54%2019: -$82.8M-$82.8M2019−28%2020: -$69.5M-$69.5M2020−16%2021: -$49.5M-$49.5M2021−29%2022: -$57.2M-$57.2M2022+16%
Fiscal year2016201720182019202020212022
Revenue$6.5M4$5.3M5$9.7M6$9.5M7$5.0M3$28.9M3$36.9M3
Cost of revenue$70.0K7$766.0K3$13.1M3$28.6M3
Research and development$48.0M4$49.6M5$82.3M6$26.4M7$15.1M3$12.6M3$14.3M3
Selling, general and admin$29.5M5$41.7M6$62.5M7$55.3M3$51.6M3$45.3M3
Operating expenses$77.4M3$92.4M3
Operating income-$55.0M4-$73.8M5-$114.4M6-$79.5M7-$66.1M3-$48.5M3-$55.5M3
Interest$75.0K4$43.0K5$133.0K6$3.4M7$1.6M3$901.0K3$698.0K3
Income before tax-$49.0M3-$55.6M3
Income tax-$672.0K4$1.4M5$49.0K6$101.0K7$139.0K3$490.0K3$1.6M3
Net income-$54.9M4-$74.4M5-$114.8M6-$82.8M7-$69.5M3-$49.5M3-$57.2M3
Earnings per share-$25.5610-$11.157-$135.233-$28.523-$21.323
Earnings per share (diluted)-$25.5610-$11.157-$135.233-$28.523-$21.323
Shares (weighted, basic)1.7M shares32.7M shares3
Shares (weighted, diluted)1.7M shares32.7M shares3

Compare Nabriva Therapeutics plc with another company

Corporate structure

Nabriva Therapeutics plc sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nabriva Therapeutics plc

  • FMR LLC Filed SC 13G/A on Nabriva Therapeutics plc, latest Feb 9, 2022
  • Lincoln Park Capital Fund, LLC Filed SC 13G on Nabriva Therapeutics plc, latest Nov 19, 2021
  • Nabriva Therapeutics plc L2

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nabriva Therapeutics plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.8M3 Dec 31, 2022$4.6M3 Dec 31, 2021+4.6%
Accumulated depreciation$4.5M3 Dec 31, 2022$4.4M3 Dec 31, 2021+3.8%
Property and equipment, net$280.0K3 Dec 31, 2022$233.0K3 Dec 31, 2021+20.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$12.4M3 Dec 31, 2022$47.7M3 Dec 31, 2021−74.0%
Marketable securities, current$16.0K3 Dec 31, 2021$16.0K7 Dec 31, 20200%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$3.0K3 Dec 31, 2022$31.0K3 Dec 31, 2021−90.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$9.7M3 Dec 31, 2022$14.5M3 Dec 31, 2021−33.3%

Leadership

Who has led Nabriva Therapeutics plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Colin Broom Md.2016–2018
  2. Theodore R. Schroeder2018–2023
  3. H. Michael Hogan Iii.2023

President

  1. Steven P. Gelone2018–2023

Chief financial officer

  1. Gary Sender2016–2021
  2. Dan Dolan2021–2022
  3. David Maggio2023

Chief operating officer

  1. Steven P. Gelone2018–2023
20202025
Board members and other officers (21)

Former names

  • Nabriva Therapeutics AGMay 14, 2015 to Jul 10, 20172

Timeline

  1. Jul 31, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale40
  2. Jul 24, 20238-K Listing notice or transfer41
  3. Jul 10, 2023New chief executive H. Michael Hogan Iii. becomes CEO12
  4. Jul 7, 20238-K Executive or director change42
  5. Jun 1, 20238-K Listing notice or transfer43
  6. Feb 6, 20238-K Entered a material agreement44
  7. Jan 20, 20238-K Executive or director change45
  8. Jan 9, 20238-K Ended a material agreement; Exit or restructuring costs; Other events46
  9. Nov 28, 20228-K Other events47
  10. Nov 10, 20228-K Results of operations48
  11. Oct 4, 20228-K Other events49
  12. Sep 16, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed50
  13. Aug 17, 20228-K Shareholder vote51
  14. Jul 27, 2018New chief executive Theodore R. Schroeder becomes CEO13
  15. Dec 30, 2016New chief executive Colin Broom Md. becomes CEO14

Calendar

When it reported results

  1. Nov 10, 2022Reported quarterly or annual results48
  2. Aug 3, 2022Reported quarterly or annual results52
  3. May 5, 2022Reported quarterly or annual results53
  4. Mar 29, 2022Reported quarterly or annual results54
  5. Jan 10, 2022Reported quarterly or annual results55
  6. Nov 9, 2021Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

159 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 25 major events, 90 insider forms, 2 large holders, 34 other. The latest 20:

  1. Oct 25, 202315-12G EDGAR
  2. Oct 24, 2023EFFECT EDGAR
  3. Oct 20, 2023POS AM EDGAR
  4. Oct 20, 2023S-8 POS EDGAR
  5. Oct 20, 2023S-8 POS EDGAR
  6. Oct 20, 2023S-8 POS EDGAR
  7. Oct 20, 2023S-8 POS EDGAR
  8. Oct 20, 2023S-8 POS EDGAR
  9. Oct 20, 2023S-8 POS EDGAR
  10. Oct 20, 2023S-8 POS EDGAR
  11. Oct 20, 2023S-8 POS EDGAR
  12. Oct 19, 202310-Q EDGAR
  13. Aug 14, 2023NT 10-Q EDGAR
  14. Jul 31, 20238-K EDGAR
  15. Jul 24, 20238-K EDGAR
  16. Jul 10, 20233 OWNERSHIP DOCUMENT EDGAR
  17. Jul 10, 20233 OWNERSHIP DOCUMENT EDGAR
  18. Jul 7, 20238-K EDGAR
  19. Jun 1, 20238-K EDGAR
  20. May 22, 202310-Q EDGAR

The 159 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 2 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 2, 2022BURGESS DANIEL DDirectorSale11,341$0.19$2.2KForm 4
Aug 2, 2022Broom Colin MDDirectorSale5,339$0.19$1.0KForm 4
Aug 2, 2022Webster Stephen WDirectorSale7,826$0.19$1.5KForm 4
Aug 2, 2022CORRIGAN MARKDirectorSale10,297$0.19$2.0KForm 4
Aug 1, 2022Rowland Charles A JrDirectorSale8,496$0.18$1.5KForm 4
Aug 1, 2022Bourdow Carrie L.DirectorSale8,540$0.17$1.5KForm 4
Dec 28, 2021Schroeder Theodore RDirectorBuy100,000$0.57$57.0KForm 4
Dec 27, 2021Naftzger J. ChristopherGeneral Counsel and Corp SecBuy7,000$0.59$4.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Nabriva Therapeutics plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNabriva Therapeutics plc1
  • CIK0001641640
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inIreland1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address25-28 North Wall Quay, Dublin, L2 D01 H1041
  • Mailing address414 Commerce Drive, Ste 120, Fort Washington, PA 190341
  • Phone(610) 816-66401
  • Shares outstanding3,230,837 as of Sep 11, 20239
  • Public float$11.6M as of Jun 30, 20223
  • On EDGAR sinceMay 14, 20151
  • Filings695 in all: 4 (319), 8-K (110), 3 (25), SC 13G/A (25), 6-K (21), 10-Q (20), 424B5 (16), CORRESP (15)1
    All 50 form types

    SC 13G (14), DEFA14A (9), S-8 POS (9), CT ORDER (8), DEF 14A (8), EFFECT (8), S-8 (8), UPLOAD (8), 10-K (7), 425 (7), 4/A (6), PRE 14A (5), F-1/A (4), SC 13D/A (4), S-3 (3), 424B3 (2), 8-K/A (2), F-6 POS (2), FWP (2), NT 10-Q (2), S-3/A (2), SC 14D9/A (2), SC TO-T/A (2), SEC STAFF LETTER (2), 15-12G (1), 20-F (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERTNAS (1), D (1), DRS (1), F-1 (1), F-3 (1), F-3/A (1), F-6 (1), NT 10-K (1), POS AM (1), S-1 (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Apr 17, 2023
    Quarterly report (10-Q) Oct 19, 2023
    Proxy statement (DEF 14A) Jul 11, 2022
    Latest 8-K (8-K) Jul 31, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59